Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Peter Pushko a Paul Pumpens b,c Elmars Grens b

a Medigen Inc., Frederick, Md., USA; b Latvian Biomedical Research and Study Centre, and c Faculty of Biology, University of Latvia, Riga, Latvia

Key Words
Virus-like particles · Three-dimensional structure · Vaccines · Drug delivery · Biotechnology

Abstract
Virus-like particle (VLP) technology is a promising approach for the construction of novel vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived from non-enveloped icosahedral or helical viruses and proved to be viable vaccine candidates due to their effective presentation of epitopes in a native conformation. VLP technology has also been used to prepare chimeric VLPs decorated with genetically fused or chemically coupled epitope stretches selected from immunologically defined target proteins. However, structural constraints associated with the rigid geometrical architecture of icosahedral or helical VLPs pose challenges for the expression and presentation of large epitopes. Complex VLPs derived from non-symmetric enveloped viruses are increasingly being used to incorporate large epitopes and even full-length foreign proteins. Pleomorphic VLPs derived from influenza or other enveloped viruses can accommodate multiple full-length and/or chimeric proteins that can be rationally designed for multifunctional purposes, including multivalent vaccines. Therefore, a second generation of VLP carriers is represented by complex particles reconstructed from natural or chimeric structural proteins derived from complex enveloped viruses. Further development of safe and efficient VLP nanotechnology may require a rational combination of both approaches.

VLP Concept and Its Evolution from Simple Icosahedral to Complex Enveloped Particles

Recombinant virus-like particles (VLPs) are nanodimensional structures that (1) are built from one or several viral structural constituents in the form of recombinant proteins synthesized in efficient homologous or primarily heterologous expression systems (bacteria, yeast, or eukaryotic cell culture); (2) are identical or closely related by their three-dimensional architecture and immunological characteristics to naturally occurring viral structures, and (3) lack genomes or infectivity [1–5]. VLPs can be formed from nucleocapsid or envelope proteins alone and the term VLP will be used here to describe any multimolecular structure formed by viral capsid and/or envelope proteins or by capsid and envelope combinations. The term non-chimeric VLPs is used for particles...
that are constructed from the original native non-modified viral proteins, whereas VLPs are defined as *chimeric* when the original structural proteins are covalently modified by the addition or substitution of foreign polypeptide stretches with functional properties, such as immunological epitopes or cell-targeting or encapsidation signals [5]. Covalent integration into chimeric VLPs can be achieved either by the expression of VLP monomer genes containing the appropriate insertions encoding the desired protein stretches [1–3, 5] or by the chemical coupling of peptides, proteins, or other molecules to VLPs [6]. Complex VLPs carrying full-length foreign proteins are defined here as *hybrids*.

Chimeric and/or hybrid VLPs target three main functional applications: (1) presentation of foreign epitopes leading to novel immunological content and subsequently to the creation of novel vaccines; (2) encapsidation of various therapeutic or diagnostic agents, such as nucleic acids as adjuvants for vaccines or gene therapy, proteins or mRNAs for diagnostic or therapeutic purposes, or low-molecular-weight drugs to be delivered to specific cells, and (3) specific targeting of desired organs, tissues, or cells.

Historically, the first two VLPs were derived from hepatitis B virus (HBV) and expressed in *Escherichia coli* and *Saccharomyces cerevisiae* during the mid-1980s. These VLPs were hepatitis B core (HBc) [7–9] and surface (HBs) [10] particles, which possessed icosahedral and octahedral symmetry, respectively [for a detailed review, see 11]. Later, the first representatives of VLPs derived from small RNA bacteriophages, non-enveloped viral proteins, whereas VLPs are defined as *chimeric*, have been used as vaccines and configured as epitope display carriers (table 1). Recombinant icosahedral and, to lesser extent, helical VLP structures provide exceptionally effective environments for a high-density symmetric display of foreign oligopeptides, whereas three-dimensional maps of VLPs allow for the rational design of sites for epitope insertion. The regular repetitive pattern and correct conformation of the initial and inserted epitopes of symmetric VLPs have been recognized as critical features for the induction of a strong immunological response and for their potential use as highly efficient vaccines [for reviews, see 5, 6, 11, 21–28].

The interest in rationally designed manipulations of chimeric VLPs has been reinforced by the determination of the structures of many viral capsids by protein X-ray crystallography. The upper part of figure 1 shows crystal structures of representative icosahedral VLPs. As is evident, VLPs have been derived from all classes of viral genomes, i.e., double- and single-stranded DNA and RNA. Thus far, most VLPs have been derived from viruses with single-stranded RNA genomes of positive polarity lacking a DNA intermediate. Complex VLPs were recently constructed from large enveloped negative-strand RNA viruses such as influenza viruses and Ebola virus (see the section ‘Complex VLPs derived from enveloped viruses’ below).

As indicated in table 1, some icosahedral and helical VLPs have been used as vaccines in their native, non-chimeric form without the introduction of foreign sequences (for references, see table 1). For example, the HBs antigen that represents 22-nm particles produced in yeast has been a successful HBV vaccine since 1986. Another structural HBV protein, a nucleocapsid or HBC particle, is being tested as a component of a therapeutic HBV vaccine (table 1). Yet another example of a native, non-chimeric VLP vaccine are human papillomavirus (HPV) VLPs produced in yeast or baculovirus expression systems, which went onto the market in 2006 and 2007, respectively, as vaccines against cervical cancer. Norwalk virus and rotavirus VLPs against the major etiologic agents of epidemic gastroenteritis in humans are currently in clinical trials.

Animal circovirus and parvovirus VLP vaccines have been designed against infections in pigs and dogs (table 1). Other animal vaccines that are based on non-modified native VLPs have been prepared against calicivirus...
(RHDV), papillomavirus (BPV and CRPV), reovirus (BTV), and birnavirus (AHSV) infections.

**Chimeric VLPs**

Table 1 lists the published chimeric VLPs (including hybrid VLPs) that have been prepared by either gene fusion or chemical coupling of epitope peptides to the VLP surface, with an emphasis on vaccine and drug delivery applications.

The earliest chimeric structures, which appeared during the mid-1980s, were either based on tobacco mosaic virus [17] or derived from HBs protein [29, 30]. The development of the HBs protein has recently resulted in the first successful phase III clinical trial of a chimeric VLP vaccine, specifically the RTS,S vaccine against malaria [31, 32]. Among icosahedral VLPs, which appeared at the same time in the 1980s, HBc and VLPs derived from RNA phages have often been used as scaffolds for the construction of both prophylactic and therapeutic vaccine candidates, which are in clinical trials. For example, single-stranded RNA phages have been extensively used for the development of therapeutic vaccines by attaching genetically fused and chemically coupled epitopes (for references, see table 1).

Among other icosahedra that have advanced to chimeric VLPs, capsids from parvoviruses (B19, PPV, and CPV), comoviruses (CPMV), nodaviruses (FHV), polyomaviruses (MuPV and HaPV), and papillomaviruses (HPV and BPV) have proved to be sufficiently flexible to retain the ability to self-assemble after genetic fusion with foreign peptides. CMV, a representative of cucumoviruses, has demonstrated the unique ability to remain replication-competent and to produce progeny of chimeric viruses carrying foreign insertions. Bromoviruses, along with the CPMV [for a review, see 33], have formed a niche of nanotechnological materials involved mostly in a variety of packaging protocols using BrMV and CCMV VLPs [for a review, see 34, 35].
### Taxonomic description of the VLP sources: family, genus, species

<table>
<thead>
<tr>
<th>Family</th>
<th>Genus</th>
<th>Species/Strain</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circoviridae</td>
<td>Circovirus</td>
<td>PCV2 (yeast)</td>
<td>native non-chimeric VLPs</td>
</tr>
<tr>
<td>Parvoviridae</td>
<td>Erythrovirus</td>
<td>B19 (insect cells)</td>
<td>chimeric and/or hybrid VLPs carrying fused or chemically conjugated epitopes/fragments from the proteins indicated below</td>
</tr>
<tr>
<td>Parvoviridae</td>
<td>Breviervirus</td>
<td>IHHNV (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Parvoviridae</td>
<td>Dependovirus</td>
<td>GPV (insect cells)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Parvoviridae</td>
<td>Parovirus</td>
<td>PPV (insect cells)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Parvoviridae</td>
<td>Parovirus</td>
<td>CPV (insect cells)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Hepeviridae</td>
<td>Hepevirus</td>
<td>HEV (plants)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Bromoviridae</td>
<td>Alfamovirus</td>
<td>Allalfa mosaic virus (AIMV)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Bromoviridae</td>
<td>Bromovirus</td>
<td>Brome mosaic virus (BrMV)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Bromoviridae</td>
<td>Bromovirus</td>
<td>Cowpea chlorotic mottle virus (CCMV)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Bromoviridae</td>
<td>Cucumovirus</td>
<td>Cucumber mosaic virus (CMV)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Leviridae</td>
<td>Levivirus</td>
<td>HIV-1 (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Enterobacteria</td>
<td>phage MS2</td>
<td>HIV-1 (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Enterobacteria</td>
<td>phage PP7</td>
<td>HIV-1 (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Enterobacteria</td>
<td>phage fr</td>
<td>HBV (Pushko P, unpubl.), HaPV [134] (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Enterobacteria</td>
<td>phage GA</td>
<td>HPV [135], CpG, LMW drugs (Renhofa R, unpubl.)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Acinetobacter</td>
<td>phage AP205</td>
<td>hypertenion, GnRH, HIV-1, influenza A</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>Leviridae</td>
<td>Allolevirus</td>
<td>Allergy, therapeutic vaccine (E. coli)</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
</tbody>
</table>

### Table 1. Summary of VLPs used for the development of vaccines, vectors/nanocontainers, and cell-targeting tools

<table>
<thead>
<tr>
<th>VLPs as vaccines and/or vaccine candidates</th>
<th>VLPs as nanocages for the transportation of the following molecules</th>
<th>VLPs as delivery tools to the specified cell targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>native non-chimeric VLPs</td>
<td>chimeric and/or hybrid VLPs carrying fused or chemically conjugated epitopes/fragments from the proteins indicated below</td>
<td>shrimps hemocytes [99]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>transferrin receptors [107]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HCC [129]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DNA, a protein and a fluorophore [121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RNA [125–130], ricin A [131], proteins and drugs [129]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RNA [135], CpG, LMW drugs (Renhofa R, unpubl.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RNA [78], enzymes [152], proteins [153], drugs [154, 155]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>targeting by ZZ domain [156], EGF targeting [157], heparin reversion [158]</td>
</tr>
</tbody>
</table>
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Taxonomic description of the VLP sources: family, genus, species</th>
<th>VLPs as vaccines and/or vaccine candidates</th>
<th>VLPs as nanocages for the transportation of the following molecules</th>
<th>VLPs as delivery tools to the specified cell targets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Leviviridae unclassified</strong></td>
<td>native non-chimeric VLPs</td>
<td>metal ion-dependent assembly</td>
<td></td>
</tr>
<tr>
<td>Caulobacter phage phiCb5</td>
<td></td>
<td>[159] (E. coli)</td>
<td></td>
</tr>
<tr>
<td><strong>Secoviridae Comovirus</strong></td>
<td>Pseudomonas aeruginosa [160], mink enteritis (MEV) [161], CPV [162] (plants)</td>
<td>nanobuilding blocks (plants) [163–166]</td>
<td></td>
</tr>
<tr>
<td>Cowpea mosaic virus (CPMV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Picornaviridae Cardiovirus</strong></td>
<td>EMCV [171] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Porcine encephalomyocarditis virus (EMCV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Picornaviridae Enterovirus</strong></td>
<td>EV71 [172] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterovirus type 71 (EV71)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coxsackievirus B</strong> (CVB3)</td>
<td>CVB3 [173] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Picornaviridae Aphthovirus</strong></td>
<td>FMDV [174] (E. coli), [175] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foot-and-mouth disease virus (FDMV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nodaviridae Alphanodavirus</strong></td>
<td>anthrax [176] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flock house virus (FHV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tombusviridae Tombusvirus</strong></td>
<td>ricin toxin [177] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tomato bushy stunt virus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nodaviridae Betanodavirus</strong></td>
<td>viral nervous necrosis (MGNV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malabaric grouper nervous necrosis virus (MGNV)</td>
<td>[178] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Caliciviridae Norovirus</strong></td>
<td>viral nervous necrosis (DGNV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norwalk virus (NV)</td>
<td>[179] (E. coli)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Caliciviridae Lagovirus</strong></td>
<td>viral nervous necrosis (RH DV)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit hemorrhagic disease virus (RHDV)</td>
<td>[180–182] (plants), [183] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Polyomaviridae Polyomavirus</strong></td>
<td>RHDV [184] (insect cells), [185] (S. cerevisiae), [186] (Pichia pastoris)</td>
<td>FMDV [187, 188], feline calivirus (FCV) [188], ovalbumin [189] (insect cells)</td>
<td>dendritic cells [190]</td>
</tr>
<tr>
<td>MuRine polyomavirus (MuPV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HBV[191] (yeast), antitumour [192–194] (insect cells), influenza [195] (E. coli)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[196]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Simian virus 40 (SV40)</strong></td>
<td>DNA [202]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>proteins [203], quantum dots [204]</td>
<td>RGD targeting [205], EGF receptor [206]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RNAi [207], DNA [208]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Papillomaviridae Alphapapillomavirus</strong></td>
<td>DNA, packaging in GFP-decorated VLPs [216], HEV ORF [217]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV: Gardasil [209] (yeast), Cervarix [210] (insect cells)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SIV/HIV [211], HPV: L1+E7 [212, 213] (insect cells), influenza [214], HPV E6, E7 [215] (plants)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J C polyomavirus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DNA delivery to dendritic cells [218], B cells [219]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taxonomic description of the VLP sources: family, genus, species</td>
<td>VLPs as vaccines and/or vaccine candidates</td>
<td>VLPs as nanocages for the transportation of the following molecules</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
<tr>
<td>-----------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><em>Papillomaviridae Deltapapillomavirus</em></td>
<td>BPV [220] (insect cells)</td>
<td>HPV [221], Alzheimer’s disease [222], antitumour [223] (insect cells)</td>
<td>DNA [224]</td>
</tr>
<tr>
<td><em>Papillomaviridae Kappapapillomavirus</em></td>
<td>CRPV [225] (S. cerevisiae), [226, 227] (insect cells), [228] (plants)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Reoviridae Orbivirus</em></td>
<td>BTV [229–232] (insect cells)</td>
<td>HBV [233], rabies virus [234], influenza [235]</td>
<td></td>
</tr>
<tr>
<td><em>African horse sickness virus (AHSV)</em></td>
<td>AHSV [236] (mammalian cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Reoviridae Rotavirus</em></td>
<td>RT [238–240], RT + noro [241] (insect cells)</td>
<td>chimeric RT, VP8 fusion to VP2 [242] (insect cells)</td>
<td>GFP [243] (insect cells)</td>
</tr>
<tr>
<td>Yeast retrotransposon Ty1</td>
<td></td>
<td></td>
<td>intestinal cells [243]</td>
</tr>
<tr>
<td><em>Podoviridae T7-like viruses</em></td>
<td></td>
<td></td>
<td>HepG2 cells [251]</td>
</tr>
<tr>
<td><em>Podoviridae P22-like viruses</em></td>
<td></td>
<td></td>
<td>small molecules, polymers, metals [252] (E. coli)</td>
</tr>
<tr>
<td><em>Siphoviridae Lambda-like viruses</em></td>
<td></td>
<td>HIV-1 [253] (E. coli, conjugation)</td>
<td></td>
</tr>
<tr>
<td><em>Adenoviridae Mastadenovirus</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human adenovirus B (type 3) (Ad3)</td>
<td></td>
<td>cancer [254] (insect cells)</td>
<td>proteins [255], bleomycin [256]</td>
</tr>
</tbody>
</table>

**Non-enveloped viruses: helical symmetry**

| Alphaflexiviridae Potexvirus | | | |
| Papaya mosaic virus (PapMV) | influenza A [257, 258] (plants) | | |
| *Potyviridae Polytivirus* | | | |
| Johnsongrass mosaic virus (JGMV) | HIV-1 [259], beet necrotic yellow vein virus (BNYYV) [260], tuberculosis [261], influenza [262], HCV [263], HPV [264, 265] (all plants) | | targeting model [266] |
| Bamboo mosaic virus (BaMV) | | FMDV [267], IBDV [268] (all plants) | |
| *Potyviridae Polytivirus* | | | |
| Plum pox virus (PPV) | Sharka disease [272] (plants) | CPV [273] (plants) | |
| *Virgaviridae Tobamovirus* | | | |
| Tobacco mosaic virus (TMV) | | | |
| | poliovirus [17] (E. coli), [275] (plants); malaria [276], influenza, HIV-1 [277], rabies virus (RV) [278], MHV [278, 279], *P. aeruginosa* [280], FMDV [281], CRPV, rabbit oral papillomavirus (ROPV) [282] (plants) | RNA [283] | |
### Table 1 (continued)

<table>
<thead>
<tr>
<th>Taxonomic description of the VLP sources: family, genus, species</th>
<th>VLPs as vaccines and/or vaccine candidates</th>
<th>VLPs as nanocages for the transportation of the following molecules</th>
<th>VLPs as delivery tools to the specified cell targets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enveloped viruses: icosahedral symmetry</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepadnaviridae Orthohepadnavirus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B virus (HBV) core (HBc) particles</td>
<td>therapeutic HBV [11, 284], combined with HBs [285] (E. coli)</td>
<td>FMDV: eukaryotic cells [286], E. coli [287], plants [288]; HPV: E. coli [289, 290], Salmonella typhimurium [291], HIV-1, HBV [11, 191], hepatocellular carcinoma [292], hanta [293, 294], HCV [295, 296], anthrax [297], Crohn’s disease [298], tuberculosis [299], influenza [300–303] (E. coli) [304] (plants), malaria [305–307], Borrelia burgdorferi [308–310], nontypeable Haemophilus influenzae [311], BBDV [312] (E. coli)</td>
<td>CpG [78, 79]; RNA, CpG, proteins, magnetic iron nanoparticles (Ren-hofa R, unpubl.)</td>
</tr>
<tr>
<td>Hepatitis B virus (HBV) surface (HBs) particles</td>
<td>HBV: Engerix-B [314], H-B-Vax II, or Recombivax HB [315] (S. cerevisiae), Heplisav [316] (Hansenula polymorpha), combined with HBc [285] (yeast), edible vaccine [317–320] (plants)</td>
<td>HSV-1 [29], HBV: preS-HBs therapeutic GenHevac B [321, 322], Bio-Hep-B [323], Hepacare (mammalian cells) [324] (mammalian cells), malaria RTS,S [31, 32] (S. cerevisiae), poliovirus 1 and 2 [30], SIV [325] (both mammalian cells), HIV-1: mammalian cells [326], yeast [327], plants [328], HPV [290] (S. cerevisiae), HEV [329], dengue [330] (both P. pastoris), HCV [331, 332], influenza [333], Helicobacter pylori [334] (all mammalian cells)</td>
<td></td>
</tr>
<tr>
<td><strong>Woodchuck hepatitis virus (WHV) core (WHc) particles</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Flaviviridae Flavivirus</strong></td>
<td>WNV [336] (mammalian cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>West Nile virus (WNV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dengue virus</td>
<td>Dengue [337] (mammalian cells), [338] (P. pastoris), [339, 340] (E. coli)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis C virus (HCV)</td>
<td>HCV [341–343] (insect cells), [344, 345] (P. pastoris)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japanese encephalitis virus (JEV)</td>
<td>JEV [346–348] (mammalian cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tick-borne encephalitis virus (TEV)</td>
<td>TEV [345] (mammalian cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Togaviridae Alphavirus</strong></td>
<td>SIN: core-like particles [349, 350] (E. coli)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sindbis virus (SIN)</td>
<td>RRV: core-like particles [349, 350] (E. coli), VLPs [351] (E. coli; mammalian cells)</td>
<td></td>
<td>gold nanoparticles [352]</td>
</tr>
<tr>
<td>Ross river virus (RRV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chikungunya virus (CHIKV)</td>
<td>CHIKV [353] (mammalian cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmon alphasivirus (SAV)</td>
<td>SAV [354] (insect cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coronaviridae Betacoronavirus</strong></td>
<td>SARS [355] (insect cells)</td>
<td>SARS influenza [48] (insect cells)</td>
<td></td>
</tr>
<tr>
<td>Severe acute respiratory syndrome-related coronavirus (SARS-CoV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Table 1 (continued)</td>
<td>VLPs as vaccines and/or vaccine candidates</td>
<td>VLPs as nanocages for the transportation of the following molecules</td>
<td>VLPs as delivery tools to the specified cell targets</td>
</tr>
</tbody>
</table>
|----------------------|------------------------------------------|------------------------------------------------|-------------------------------------------------
| **Taxonomic description of the VLP sources: family, genus, species** | | | |
| **Bunyaviridae Nairovirus** | Crimean-Congo hemorrhagic fever (CCHF) virus | CCHF [356] (insect cells) | |
| **Bunyaviridae Phlebovirus** | Rift Valley fever virus (RVFV) | RVFV [357] (mammalian cells) | |
| **Bunyaviridae Hantavirus** | Hantaan virus (HTNV) | HTNV [358] (mammalian cells) | |
| **Retroviridae Lentivirus** | Human immunodeficiency virus 1 (HIV-1) | HIV-1 [356] (mammalian cells), [46, 364] (insect cells), pseudorabies virus [366] (both insect cells), HPV [367] (mammalian cells) | proteins [368–370] |
| **Human immunodeficiency virus 2 (HIV-2)** | HIV-2 [371] (insect cells) | HIV-1 and HIV-2 [372, 373] (insect cells) | proteins [368] |
| **Simian immunodeficiency virus (SIV)** | SIV [374] (mammalian cells), [375] (insect cells) | SHIV [376, 377] (insect cells) | |
| **Retroviridae Alpharetrovirus** | Rous sarcoma virus (Rous SV) | human prorenin receptor (hPRR) [379] (insect cells) | |
| **Retroviridae Gammaretrovirus** | Murine leukemia virus (MLV) | Alzheimer’s disease [380], prion disease [381], VSV [382], cytokines [383], influenza [384] (all insect cells) | |
| **Herpesviridae Lymphocryptovirus** | Human herpesvirus 4 (Epstein-Barr virus, EBV) | EBV [385] (mammalian cells) | |
| **Arenaviridae Arenavirus** | Lassa virus | Lassa virus [45] (mammalian cells) | Tacaribe and Junin viruses [391] |
| **Paramyxoviridae Avulavirus** | Newcastle disease virus | RSV-NDV (avian) [47, 76] | |
| **Respiratory syncytial virus (RSV)** | | | |
| **Paramyxoviridae Henipavirus** | Nipah virus (NIV) | NIV [392] (mammalian cells) | |
| **Paramyxoviridae Respirovirus** | Sendai virus (SeV) | SeV [393] (mammalian cells), [87] (S. cerevisiae) | |
| **Human parainfluenza virus 1 and 3** | | | |
| **Paramyxoviridae Rubulavirus** | Mumps virus (MuV) | MuV [394] (mammalian cells), [85] (S. cerevisiae) | |
Rod-shaped plant viruses of helical symmetry provide a number of replication-competent examples allowing the production of chimeric viruses, with the exception of potexviruses (papaya and bamboo mosaic viruses and PVX) and some potyviruses (JGMV, PVA, and PVY), which accept foreign insertions in the VLPs after propagation in E. coli and baculovirus expression systems (for references, see Table 1).

**Complex VLPs Derived from Enveloped Viruses**

*Construction of Complex Enveloped VLPs*

Enveloped viruses are widely used for the development of VLPs. The viral envelope represents a lipoprotein membrane that surrounds a nucleocapsid [36, 37]. The lipid bilayer is derived from host cell membranes and contains embedded viral proteins responsible for receptor recognition or other functions. It can also include carbohydrates and proteins derived from the host cell. Envelope proteins usually contain hydrophobic domains that allow their localization within the lipid bilayer. Similar to non-enveloped VLPs, the repeated regular patterns of epitopes in the native conformation make complex enveloped VLPs exceptionally effective immunogens [24, 38].

From the point of view of their spatial structure, the majority of viral envelopes are asymmetrical. However, for some enveloped viruses, viral proteins within the envelope reflect the symmetry of the inner nucleocapsid. For example, alphaviruses contain 240 heterodimers of E2-E1 proteins arranged in an icosahedral lattice according to the 240 subunits of the capsid protein within the inner icosahedral nucleocapsid [39, 40]. Other viruses, such as the orthomyxovirus influenza virus, contain envelopes that do not possess an apparent regular geometric symmetry, although they may contain elements of symmetry such as the trimers of hemagglutinin (HA) or tetramers of neuraminidase (NA) in influenza viruses.

The preparation of complex enveloped VLPs is challenging. Unlike simple icosahedral particles, enveloped VLPs often contain multiple species of lipid-associated structural proteins. In most cases, the protein-protein interactions and the roles of the proteins, lipids, and host cell factors in the assembly of VLPs are not fully understood. To achieve correct assembly of enveloped VLPs, proper interactions must occur between the nucleocapsid proteins, between the envelope proteins within the lipid bilayer, and between the envelope and the nucleocapsid proteins. The production must include an appropriate cell line and expression system, which should express suf-
icient quantities of enveloped VLPs that are immunologically similar to their cognate virus, including the arrangement of the proteins within the envelope. Furthermore, purification of enveloped VLPs can be a difficult task. During production and purification of VLPs, various cellular lipids, carbohydrates, proteins, and nucleic acids co-purify with VLPs, which may cause difficulties in purification as well as safety and regulatory concerns if VLPs are intended for clinical applications.

Despite the challenges, enveloped VLPs of several viruses have been constructed, including VLPs for HIV, influenza viruses, Ebola virus, Lassa virus, and other viruses (table 1). VLPs have been shown to induce advantageous immune responses compared with soluble recombinant proteins. For example, membrane-embedded HIV-1 envelope proteins on the surface of VLPs elicited broader immune responses than did soluble envelope proteins [41]. Similarly, influenza VLPs containing HA protein within the envelope demonstrated greater immunogenicity than subunit HA [19, 42, 43]. In some studies, native enveloped VLPs could be made with unmodified viral proteins [19, 38, 44–46]. In other cases, extensive optimization and engineering of component proteins were required to generate VLPs [46–48].

**Rational Design of Enveloped VLPs**

Rational design of VLPs has been used extensively to improve the properties of enveloped VLPs, including expression levels, stability, immunogenicity, and other characteristics. First, attempts have been made to improve the expression of component proteins to improve the production of the assembled VLPs. For example, co-codon optimization of the expressed viral genes has improved the expression of HIV and HTLV-1 VLPs [49, 50]. Second, efforts have been made to optimize the composition of VLPs and the interactions between the individual VLP components. For example, in many cases, influenza VLPs were prepared using HA, NA, and M1 proteins derived from the same strain [19, 42–44]. Other configurations of VLPs have included a heterologous M1 derived from an unrelated influenza virus strain [51] or even a retrovirus Gag protein in place of M1 [52]. Furthermore, influenza VLPs have been made from HA and NA only [53], from HA and M1 proteins only [54], and from NA and M1 only [55]. VLPs have also been generated in the presence of additional influenza virus proteins, such as M2 [56–58], or in the presence of immunostimulatory antigens such as flagellin, a ligand for Toll-like receptor 5 [59]. These studies have helped elucidate the contributions of individual components to influenza VLP formation. For example, M1 protein is the major component of the virus and an important antigen due to the presence of subtype cross-reactive epitopes [60]. However, the role of M1 in the formation of VLPs or viral particles is not completely understood. According to one view, M1 is the driving force for influenza virus particle formation, penetrating through the cell membrane from inside the cell and interacting with the cytoplasmic tails (CT) of the structural glycoproteins HA and NA during budding [61–63]. An alternative model suggests that HA and NA partition into lipid raft micro-domains and recruit the internal viral components, including M1, into the budding viral particle [53]. VLP studies have shown that VLPs can be formed either with or without M1, suggesting both M1-dependent and M1-independent mechanisms of VLP formation. This hypothesis is further supported by the fact that both M1-deficient and M1-containing types of the mature enveloped virions have been observed by cryo-electron microscopy [64].

Rational design has also been applied to HIV VLPs to improve immunogenicity and efficacy. One approach utilized consensus Env protein sequences [65]. To address the sequence diversity in Env sequences, consensus sequences were made for clade B and clade C envelope proteins. The rationale for using a consensus sequence is that the genetic difference between the vaccine strain and any given viral isolate is decreased, and, therefore, a consensus sequence will provide broader vaccine coverage. The consensus Env sequence elicited broader cell-mediated peripheral and mucosal immune responses than did polyvalent and monovalent Env protein vaccines [65]. In another study, the consensus approach was combined with protein engineering methods to increase the density of Env glycoprotein within the VLP envelopes [46]. Chimeric Env gene constructs have been engineered, in which the coding sequences for the signal peptide (SP), transmembrane (TM), and CT domains of HIV-1 Env were replaced with those of other viral or cellular proteins. Substitution of the SP from the honeybee mellitin protein resulted in 3-fold higher expression of recombinant HIV-1 Env on insect cell surfaces and increased Env incorporation into VLPs. Substitution of the HIV TM-CT with sequences derived from mouse mammary tumour virus (MMTV) envelope glycoprotein, influenza virus HA, or baculovirus (BV) gp64, but not Lassa fever virus glycoprotein, was shown to enhance Env incorporation into VLPs. The highest level of Env incorporation into VLPs was observed in constructs containing the MMTV and BV gp64 TM-CT domains in which the Gag/
Env molar ratios were estimated to be 4:1 and 5:1, respectively, compared with a 56:1 ratio for full-length consensus gp160 [46].

Additional examples of rational design include engineering of simian human immunodeficiency virus (SHIV) VLPs containing mutant HIV Env with reduced glycosylation, variable loop-deleted mutations, or combinations of both types of mutations [66].

**Presentation of Foreign Proteins within Enveloped VLPs**

Unlike VLPs from icosahedral viruses such as HPV, which are composed of a specific number of subunits symmetrically arranged in a geometric structure [67, 68], enveloped VLPs allow considerable structural flexibility. The lipid bilayer is relatively fluid, allowing greater flexibility than the rigid geometric lattice of icosahedral VLPs. This flexibility may provide considerable structural capacity and allow the expression of large epitopes or even entire foreign proteins as an integral part of enveloped VLPs.

In addition to accommodating larger foreign epitopes, the structural flexibility of enveloped VLPs makes possible the preparation of chimeric and hybrid VLPs that co-localize proteins from distinct strains or even from distinct viruses.

Influenza VLPs have been used as carriers for foreign antigenic epitopes or proteins. For example, it has been shown that influenza VLPs can incorporate vesicular stomatitis virus (VSV) G protein [56]. As mentioned previously, influenza VLPs can also incorporate flagellin [59]. In another study, *Bacillus anthracis* protective antigen (BPA) fragments 90 or 140 aa in length were inserted at the C-terminal flank of the HA SP and expressed as the HA1 subunit [69]. The chimeric proteins could be cleaved into the HA1 and HA2 subunits by trypsin and incorporated into influenza viruses, suggesting that the viral envelope can tolerate foreign insertions without precluding assembly. The inserted BPA domains were maintained in the HA gene segments following several passages in MDCK cells or embryonated chicken eggs. Immunization of mice with viruses that expressed the chimeric BPA/HA proteins induced antibody responses against both the HA and BPA components of the protein [69]. Although VLPs were not generated in this study, these experiments suggest that similar modifications of HA with foreign epitopes may be compatible with the formation of chimeric influenza VLPs.

A novel influenza VLP platform containing HA subtypes derived from three distinct strains has also been reported [70]. This recombinant VLP design resulted in the expression of three HA subtypes co-localized within a VLP (fig. 2). Experimental triple-HA VLPs containing HA proteins derived from seasonal H1N1, H3N2, and type B influenza viruses were immunogenic and protected ferrets from challenge with all three seasonal viruses. Similarly, VLPs containing HA subtypes derived from H5N1, H7N2, and H2N2 viruses protected ferrets from three potentially pandemic influenza viruses [70]. This technology may represent a novel strategy for the rapid development of trivalent seasonal and pandemic influenza vaccines.

The possibility of co-localizing proteins from distinct viruses within the VLP is somewhat similar to the phenotypic mixing that has been observed with live viruses. Phenotypic mixing of proteins from different enveloped viruses has been described between SV5, a paramyxovirus, and VSV, a rhabdovirus, as well as between Sendai and VSV [71, 72]. Reassortant viruses have also been generated by co-infection of embryonated chicken eggs with influenza type A and type B viruses [73]. Recently, live-attenuated chimeric viruses containing HA from A/PR8 (H1), A/HK68 (H3), or A/VN (H5) strains in the backbone of the B/Yamagata/88 virus were reported [74]. Re-assortment is routinely used in licensed influenza vaccines. In the reassortant vaccine virus, vaccine-relevant HA and NA glycoproteins are embedded into the envelope, whereas other viral proteins are derived from type-specific donor strains, such as the A/PR/8/34 (H1N1) or B/Ann Arbor/1/66 viruses [75].

In some cases, foreign antigens can only be expressed as VLPs by displaying them within chimeric/hybrid VLPs. For example, VLPs composed entirely of RSV proteins were produced at levels that were inadequate for their use as vaccines [47]. However, VLPs composed of the Newcastle disease virus (NDV) nucleocapsid and membrane proteins and chimeric proteins containing the ectodomains of RSV F and G proteins fused to the TM and cytoplasmic domains of NDV F and HN proteins, respectively, were quantitatively prepared from cultured avian cells. Immunization with a single dose of VLPs resulted in the complete protection of mice against RSV replication in lungs [47]. Another chimeric VLP was composed of the NP and M proteins of NDV and a chimeric protein containing the cytoplasmic and TM domains of the NDV HN protein and the ectodomain of the human RSV G protein (H/G) [76]. The VLP-H/G candidate vaccine was immunogenic in BALB/c mice and prevented replication of RSV in murine lungs with no evidence of immunopathology [76]. Chimeric VLPs consist-
ing of an influenza virus matrix (M1) protein core and RSV-F or RSV-G on the surface have also been produced [77]. These data support the further development of VLPs as vaccines for protection against RSV.

Similar to RSV VLPs, VLPs composed entirely of SARS-CoV proteins have been produced at low levels [48]. A method was developed to produce higher levels of SARS VLPs containing the SARS spike (S) protein and the influenza M1 protein (fig. 3). The SARS VLPs protected mice from death when administered via the intramuscular or intranasal routes [48].

Conclusions

It has been more than 25 years since the idea of using highly symmetric self-assembling VLPs for vaccine purposes attracted considerable attention (fig. 1). Applications of VLPs have included their use as carriers to improve the immunogenicity of poorly immunogenic epitopes. With time, over-optimistic expectations for simple and rapid generation of effective VLP-based vaccines have encountered numerous challenges. Nevertheless, as shown in this review, many promising vaccine candidates have been produced (table 1). Renewal of the
previous optimism is due at least in part to the recent development of VLPs of large complex viruses, such as orthomyxoviruses, filoviruses, and paramyxoviruses. Due to their larger size and versatile structure, complex VLPs demonstrate greater capacity and flexibility than highly symmetric icosahedral VLPs for the inclusion of full-length, properly folded foreign proteins. Furthermore, complex VLPs are capable of simultaneously accepting various foreign proteins, enabling construction of multivalent vaccines. Full-length foreign proteins or epitopes delivered by large complex VLPs offer many immunological advantages over short epitopes, which have been inserted onto the surface of icosahedral scaffolds. First, complex VLPs can enhance T helper and cytotoxic T cell responses by inducing highly specific immunological responses directed against conformational epitopes, which is difficult to achieve with chimeric symmetric VLPs. Second, due to their size and organization, complex VLPs may be stable in the blood and thereby obviate the need for adjuvants. Third, if necessary, complex VLPs can be configured to contain specific and efficient adjuvants, including immune stimulatory sequences such as CpGs [78–81]. The presence of a lipid envelope may contribute to the correct folding of certain vaccine antigens and thereby improve immunogenicity. For example, the immunogenicity of purified subunit HA could be improved by adding liposomes [19]. The immunogenicity of split influenza vaccines could also be improved by adding liposomes or lipid-based adjuvants, such as MF59, an oil-in-water emulsion containing the unsaturated aliphatic hydrocarbon squalene [82]. Interestingly, highly immunogenic influenza vaccines, such as whole virus vaccines, VLPs, and virosomes, all have a lipid component in common, suggesting that lipids may play an important role in influenza vaccine immunogenicity.

Growing interest in knowledge-based applications of complex VLPs is strengthened by the development of high-resolution methods [64, 83, 84]. The rapid development of therapeutic candidates based on complex VLPs is propelled by the constant progress of cGMP-compliant production systems, such as baculovirus system-driven production, and the recent approval of a baculovirus-derived HPV VLP vaccine by the US Food and Drug Administration and other regulatory agencies (table 1). However, purification of complex enveloped VLPs to a standard that meets regulatory and safety requirements can be a difficult task. Unlike icosahedral VLPs such as HPV, complex enveloped VLPs are difficult to purify by conventional methods such as re-folding in vitro. Therefore, the icosahedral VLP platform remains a good option for many applications due to the advantages of purification as well as a clear regulatory pathway due to the availability of licensed vaccines. The introduction of yeast expression systems into the production of complex VLPs can potentially improve the safety and quality control of biotechnological processes [85–91].

One potential method for the development of VLP-based vaccines may involve the combination of both complex and icosahedral particles, from a simple mixing of potential vaccine candidates (e.g., the therapeutic hepatitis B vaccine DV-601, http://www.dynavax.com/hepatitis_bt.html) to the knowledge-based packaging of small icosahedral VLPs into large complex VLPs in the future.

Finally, both symmetric and complex VLPs, which were initially used primarily for vaccine development, are now evolving in the direction of broader applications, including gene and drug therapies. New applications for VLPs include the targeting of specific cells and encapsidation of new materials, from oligonucleotides, genes, proteins, and peptides to therapeutic drugs and inorganic compounds such as gold and iron nanoparticles. For each application, careful consideration of both non-enveloped and enveloped VLPs may be necessary.

Acknowledgments

We are grateful to Vijay S. Reddy (San Diego, Calif., USA) for the three-dimensional images of VLPs, to Kaspars Tars, Andris Dishlers, and Andris Zeltins for critical reading of the manuscript, and to Regina Renhofa and Andris Kazaks (Riga, Latvia) for providing unpublished data. This work was supported by USDA grant 2011-33610-30433 (P. Pushko) and Latvian grants 2010/0261/2DP/2.1.1.1.0/10/APIA/VIAA/052 and 2010/0224/2DP/2.1.1.1.0/10/APIA/VIAA/164.

References


From Highly Symmetric to Complex VLP Carriers

Intervirology 2013;56:141–165
DOI: 10.1159/000346773


44 Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G: Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective im-

45 Branco LM, Grove JN, Gesske FJ, Boisen ML, Muncy IJ, Maglaito SA, Henderson LA, Schoepf RJ, Cashman KA, Hensley LE, Garry RF: Lassa virus-like particles displaying all major immunological determinants as a vacci-


47 McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare JM, Smith G, Schmidt MR, Morrison TG: Assembly and immunological properties of Newcastle dis-


51 Terajima M, Cruz J, Leporati AM, Orphin L, Wang BZ, Quan FS, Kang SM, Bozja J, Vzorov A, Compans RW, Kang SM: Influenza M1 VLPs containing neuraminidase induce heterosubtypic immunity against homologous and heterolo-

52 Harris A, Cardone G, Winkler DC, Heymann J, Kawaoka Y: Immunogenicity and protec-


54 Quan FS, Huang C, Comps RW, Kang SM: Virus-like particle vaccine induces protective immunity against homologous and heterolo-

55 Quan FS, Kim MC, Lee BJ, Song JM, Comps RW, Kang SM: Influenza M1 VLPs contain-


57 Matassov D, Cupo A, Galarza JM: A novel in-

58 Dodge T, Haynes M, Smith G, Hahn BH, Comps RW: Incorporation of high levels of chimeric human immunodeficiency virus en-


60 Terajima M, Cruz J, Leporati AM, Orphin L, Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW: Influenza virus-like particle vaccine induces protection against respi-

61 Gómez-Puertas P, Albo C, Pérez-Pastrana E, Vivo A, Portela A: Influenza virus matrix pro-

62 Schmitt AP, Lamb RA: Influenza virus assem-

63 Schmitt AP, Lamb RA: Influenza virus assem-


65 McBurney SP, Ross TM: Human immunodefi-

66 Schmitt AP, Lamb RA: Influenza virus assem-


68 Sasagawa T, Pushko P, Steers G, Gschmeiss-


71 Choppin PW, Comps RW: Phenotypic mixing of envelope proteins of the parainfluen-


73 Gotlib E, Hirst GK: The experimental pro-


75 Chen Z, Aspelund A, Kemble G, Jin H: Mo-

76 Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Hea-

77 Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, Comps RW, Kang SM: Immunoge-


79 Li ZN, Mueller SN, Ye L, Bu Z, Yang C, Ahmed R, Steinhauser DA: Chimeric influen-


81 Choppin PW, Comps RW: Phenotypic mixing of envelope proteins of the parainfluen-


83 Gotlib E, Hirst GK: The experimental pro-


85 Chen Z, Aspelund A, Kemble G, Jin H: Molec-


87 Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, Comps RW, Kang SM: Virus-like particle vaccine induces protection against respi-


89 Li ZN, Mueller SN, Ye L, Bu Z, Yang C, Ahmed R, Steinhauser DA: Chimeric influen-


91 Choppin PW, Comps RW: Phenotypic mixing of envelope proteins of the parainfluen-


93 Gotlib E, Hirst GK: The experimental pro-


95 Chen Z, Aspelund A, Kemble G, Jin H: Molec-

96 Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Hea-

97 Quan FS, Sailaja G, Skountzou I, Huang C, Vzorov A, Comps RW, Kang SM: Virus-like particle vaccine induces protection against respi-


99 Li ZN, Mueller SN, Ye L, Bu Z, Yang C, Ahmed R, Steinhauser DA: Chimeric influen-

From Highly Symmetric to Complex VLP Carriers

Interivirology 2013;56:141–165
DOI: 10.1159/000346773


Schlienger K, Montefiori DC, Mancini M, Virotte Y, Tioliats P, Michel ML. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol 1994;68:6578–6588.


351 Falcón V, García C, de la Rosa MC, Menén dez I, Seoane J, Grillo JM: Ultrastructural and immunochemistry evidence of core-particle formation in the methylotroph 


From Highly Symmetric to Complex VLP Carriers


